The complete response letter for Lytenava that Outlook Therapeutics, Inc. revealed on 30 August parallels in many ways the challenges of the wet age-related macular degeneration market that firm is trying to enter with its proprietary formulation of bevacizumab: It is both straightforward and elusive.
About 50% of the wet AMD patients in the US are treated with compounded versions of I.V. bevacizumab, which leads...








